Bio & Pharma
Ybrain, Chong Kun Dang join forces for digital medicine distribution
Chong Kun Dang will have exclusive supply rights and sell Mindd Stim to S.Korean psychiatrists
By Jan 31, 2023 (Gmt+09:00)
1
Min read
Most Read
LG Chem to sell water filter business to Glenwood PE for $692 million


Kyobo Life poised to buy Japan’s SBI Group-owned savings bank


KT&G eyes overseas M&A after rejecting activist fund's offer


StockX in merger talks with Naver’s online reseller Kream


Mirae Asset to be named Korea Post’s core real estate fund operator



South Korean electroceutical platform company Ybrain Inc. said on Tuesday it has entered into a joint promotion agreement with Chong Kun Dang Pharmaceutical Corp. for the distribution of its bioelectronic medicine device Mindd Stim.
The device is used to treat symptoms of depression through electrical stimulation.
Under the terms of the agreement, Chong Kun Dang will have exclusive supply rights and sell the product to domestic psychiatrists, while Ybrain will handle product installation and customer inquiries.
"Our goal for 2023 is to become a globally competitive leader in digital medicine and customized medicines," said Kim Young-joo, CEO of Chong Kun Dang.
"With this agreement in place, we aim to diagnose depression earlier and create a more favorable treatment environment in Korea," said Lee Ki-won, CEO of Ybrain.
Write to Yoorim Kim at youforest@hankyung.com
More to Read
-
Bio & PharmaDaewoong Pharma, Neurolive to jointly develop new antidepressant drug
Dec 28, 2022 (Gmt+09:00)
1 Min read -
Korean startupsMental health app Spring Health emerges amid pandemic
Nov 29, 2021 (Gmt+09:00)
3 Min read
Comment 0
LOG IN